Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from OCGN

Ocugen Shares Are Trading Higher Monday: What's Going On?

Ocugen, Inc. (NASDAQ:OCGN) shares traded higher on Monday after the company announced a licensing agreement with Kwangdong Pharmaceutical for the exclusive Korean rights to OCU400.

Ocugen (OCGN) Shares Slide Following Merger Agreement: What's Going On?

Ocugen (OCGN) Shares Slide Following Merger Agreement: What's Going On?

Shares of Ocugen Inc (NASDAQ:OCGN) are trading lower by more than 8% Monday afternoon. The company earlier announced a definitive agreement to merge its subsidiary OrthoCellix with Carisma Therapeutics in an all-stock deal.

3 Standout Penny Stocks to Watch This April

3 Standout Penny Stocks to Watch This April

Investing in penny stocks carries substantial risk, but also offers the potential for significant returns. These penny stocks, all with bullish analyst ratings, have considerable upside potential, according to Wall Street.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Stay Away From These 3 Stocks With Bearish Momentum in April

Coupled with fears about an economic downturn, several other headwinds could keep the biotechnology industry under significant pressure. Given this backdrop, fundamentally weak biotech stocks Day One Biopharmaceuticals (DAWN), Northwest Biotherapeutics (NWBO), and Ocugen (OCGN), with bearish momentum, could be avoided in April. Read on….

Ocugen's Partner COVID-19 Vaccine Covaxin Shows Encouraging Action In Children Below 18 Years

Ocugen Inc (NASDAQ:OCGN) announced the publication of positive pediatric Phase 2/3 study results in children aged 2–18 years for COVID-19 vaccine, Covaxin (BBV152), in The Lancet Infectious Diseases. Covaxin is developed and manufactured by Ocugen's India-based partner Bharat Biotech International Limited. It is under clinical investigation by Ocugen in the U.S. for use…

Ocugen Diversifies Its Pipeline With New Cell Therapy Platform

Ocugen Inc (NASDAQ:OCGN) says it is diversifying its pipeline by introducing a Phase 3 cell therapy platform technology called NeoCart (autologous chondrocyte-derived neocartilage). Recently, the FDA granted a Regenerative Medicine Advanced Therapy (RMAT) designation to NeoCart to repair full-thickness lesions of the knee cartilage in adults. NeoCart is a three-dimensional tissue-engineered disc of…

FDA Removes Clinical Hold On Ocugen's COVID Vaccine Trial

The FDA has lifted the clinical hold on Ocugen Inc's (NASDAQ:OCGN) Phase 2/3 trial, OCU-002, for Covaxin (BBV152), a whole virus inactivated COVID-19 vaccine candidate. In April, the agency paused the trials of the shot, Covaxin, after an inspection of a Bharat Biotech facility by the World Health Organization (WHO) revealed deficiencies…

inkl

Read news from The Economist, FT, and more,
with one subscription

Why Ocugen Shares Are Trading Higher Today

Why Ocugen Shares Are Trading Higher Today

Ocugen Inc (NASDAQ:OCGN) and Bharat Biotech have amended their co-development, supply, and commercialization agreement to expand Ocugen's exclusive territory to include the commercialization of Covaxin in Mexico. This gives Ocugen Covaxin commercialization rights for all of North America. Covaxin can be an ideal vaccination option for Mexico at this pandemic stage. As a whole…

Read Why Did WHO Suspend UN Supply of Bharat Biotech's Covaxin COVID-19 Vaccine

Read Why Did WHO Suspend UN Supply of Bharat Biotech's Covaxin COVID-19 Vaccine

According to Reuters, the World Health Organization suspended the supply of Covaxin through UN agencies for the COVID-19 vaccine. WHO said it would allow the manufacturer to improve its facilities and address issues found in a WHO post-emergency use listing (EUL) inspection of Bharat Biotech's manufacturing. The details of what…

FDA Denies Pediatric EUA To Ocugen For Bharat Biotech's COVID-19 Vaccine Covaxin

FDA Denies Pediatric EUA To Ocugen For Bharat Biotech's COVID-19 Vaccine Covaxin

The FDA has declined to issue an Emergency Use Authorization (EUA) for Covaxin for active immunization to prevent COVID-19 in individuals 2 to 18 years of age. Ocugen Inc (NASDAQ:OCGN) is working with the vaccine's developer, Bharat Biotech of India, to bring Covaxin to the U.S. Related: FDA Lifts Clinical Hold On Ocugen's COVID-19…

Recap: Ocugen Q4 Earnings

Recap: Ocugen Q4 Earnings

Ocugen (NASDAQ:OCGN) reported its Q4 earnings results on Friday, February 25, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Ocugen To Buy Liminal's Dormant Vaccine Manufacturing Plant In Canada

Ocugen To Buy Liminal's Dormant Vaccine Manufacturing Plant In Canada

Ocugen Inc (NASDAQ: OCGN) has

1

People

Sristi Suman JayaswalThe

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

World Health Organization

Indian Council of Medical Research

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

354,641 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play